Get the Stockscreener App
42.84
1.47%
0.62
Veracyte Inc stock is traded at $42.84, with a volume of 821.56K.
It is up +1.47% in the last 24 hours and up +1.28% over the past month.
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder). In addition, its Percepta Nasal Swab test is being run in CLIA labs in support of clinical studies.
See More
Previous Close:
$42.22
Open:
$42.26
24h Volume:
821.56K
Relative Volume:
0.86
Market Cap:
$3.39B
Revenue:
$399.58M
Net Income/Loss:
$-54.04M
P/E Ratio:
-57.12
EPS:
-0.75
Net Cash Flow:
$40.13M
1W Performance:
-3.97%
1M Performance:
+1.28%
6M Performance:
+60.51%
1Y Performance:
-3.51%
1-Day Range:
$41.55
$43.41
1-Week Range:
$41.55
$45.16
52-Week Range:
$22.61
$50.71
Veracyte Inc Stock (VCYT) Company Profile
Name
Veracyte Inc
Sector
Industry
Phone
(650) 243-6300
Address
6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA
Compare VCYT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VCYT
Veracyte Inc
|
42.84 | 3.34B | 399.58M | -54.04M | 40.13M | -0.75 |
|
TMO
Thermo Fisher Scientific Inc
|
572.28 | 217.50B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
226.33 | 164.13B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
704.20 | 56.49B | 4.17B | 1.03B | 940.22M | 12.61 |
|
A
Agilent Technologies Inc
|
139.68 | 40.44B | 6.95B | 1.30B | 1.15B | 4.5714 |
|
IQV
Iqvia Holdings Inc
|
222.26 | 38.48B | 15.90B | 1.28B | 2.21B | 7.2842 |
Veracyte Inc Stock (VCYT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-25 | Resumed | Morgan Stanley | Underweight |
| Oct-20-25 | Initiated | Canaccord Genuity | Hold |
| Mar-20-25 | Initiated | Craig Hallum | Buy |
| Dec-05-24 | Downgrade | Goldman | Buy → Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-16-24 | Initiated | UBS | Buy |
| Oct-10-24 | Initiated | Guggenheim | Buy |
| Feb-23-24 | Reiterated | Needham | Buy |
| Jan-18-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Jan-07-22 | Initiated | Stephens | Overweight |
| Nov-18-21 | Resumed | Goldman | Buy |
| Jun-15-21 | Initiated | Raymond James | Outperform |
| Feb-18-21 | Resumed | Needham | Buy |
| Jan-28-21 | Initiated | Truist | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Sep-09-20 | Initiated | Morgan Stanley | Underweight |
| Jul-31-19 | Initiated | Lake Street | Buy |
| Jul-02-19 | Initiated | Needham | Buy |
| Nov-29-18 | Downgrade | Janney | Buy → Neutral |
| Oct-31-18 | Upgrade | Janney | Neutral → Buy |
| Nov-07-17 | Downgrade | Janney | Buy → Neutral |
| Nov-07-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Aug-31-17 | Resumed | BTIG Research | Buy |
| Nov-14-16 | Resumed | Leerink Partners | Outperform |
| Dec-18-15 | Initiated | Cantor Fitzgerald | Buy |
| Jun-11-15 | Reiterated | Leerink Partners | Outperform |
| Nov-26-13 | Initiated | William Blair | Outperform |
View All
Veracyte Inc Stock (VCYT) Latest News
Veracyte, Inc. $VCYT Shares Sold by Nikko Asset Management Americas Inc. - MarketBeat
Veracyte (NASDAQ:VCYT) Stock Rating Lowered by Wall Street Zen - MarketBeat
PLSE Starts Research Work on nPulse Technology to Treat Thyroid Tumor - sharewise.com
Next Century Growth Investors LLC Lowers Stock Holdings in Veracyte, Inc. $VCYT - MarketBeat
JPMorgan Chase & Co. Buys 243,111 Shares of Veracyte, Inc. $VCYT - MarketBeat
Eastham (Veracyte director) sells $908k in VCYT stock By Investing.com - Investing.com Canada
Insider Selling: Veracyte (NASDAQ:VCYT) Director Sells 20,000 Shares of Stock - MarketBeat
Eastham (Veracyte director) sells $908k in VCYT stock - Investing.com
Veracyte Insider Sold Shares Worth $908,923, According to a Recent SEC Filing - marketscreener.com
Beat the Market the Zacks Way: Veracyte, Las Vegas Sands, 3M in Focus - Yahoo Finance
Prudential Financial Inc. Has $1 Million Position in Veracyte, Inc. $VCYT - MarketBeat
Investment Report: How analysts rate Veracyte Inc stock todayJuly 2025 Gainers & AI Driven Price Predictions - moha.gov.vn
Veracyte (NASDAQ:VCYT) Shares Down 4.5% on Insider Selling - MarketBeat
Insider Selling: Veracyte (NASDAQ:VCYT) Insider Sells 1,278 Shares of Stock - MarketBeat
Veracyte (NASDAQ:VCYT) CEO Marc Stapley Sells 7,668 Shares - MarketBeat
Annie Mcguire Sells 1,422 Shares of Veracyte (NASDAQ:VCYT) Stock - MarketBeat
Insider Selling: Veracyte (NASDAQ:VCYT) CFO Sells 13,278 Shares of Stock - MarketBeat
Will Veracyte Inc. (12V) stock profit from fiscal stimulusVolume Spike & Precise Buy Zone Identification - Newser
Can Veracyte Inc. (12V) stock sustain breakout momentumQuarterly Profit Summary & Low Drawdown Trading Techniques - Newser
Veracyte (VCYT): CFO Chambers sells $621,955 in shares By Investing.com - Investing.com Australia
Veracyte NASDAQ:VCYT CEO Stapley sells $361k in shares By Investing.com - Investing.com UK
Veracyte VCYT: chief commercial officer Leite sells $61k in stock - Investing.com Canada
Annie Mcguire, Veracyte SVP, sold $67k in VCYT stock By Investing.com - Investing.com Canada
Annie Mcguire, Veracyte SVP, sold $67k in VCYT stock - Investing.com
Veracyte (VCYT): CFO Chambers sells $621,955 in shares - Investing.com India
Will Veracyte Inc. (12V) stock benefit from infrastructure billJuly 2025 Update & Real-Time Chart Pattern Alerts - Newser
Panagora Asset Management Inc. Sells 41,108 Shares of Veracyte, Inc. $VCYT - MarketBeat
Can Veracyte Inc. (12V) stock sustain revenue momentum2025 Price Action Summary & Safe Entry Zone Tips - Newser
Capital Fund Management S.A. Takes Position in Veracyte, Inc. $VCYT - MarketBeat
Is Veracyte Inc. (12V) stock resilient in recession scenariosJuly 2025 Retail & Daily Chart Pattern Signals - Newser
Is Veracyte Inc. (12V) stock nearing a technical breakout2025 Fundamental Recap & Weekly High Return Forecasts - Newser
Veracyte NASDAQ:VCYT CEO Stapley sells $361k in shares - Investing.com
Veracyte, Inc. (VCYT) Stock Forecasts - Yahoo Finance
Loomis Sayles & Co. L P Trims Position in Veracyte, Inc. $VCYT - MarketBeat
Veracyte assumed with an Underweight at Morgan Stanley - MSN
Why Veracyte (VCYT) is a Top Growth Stock for the Long-Term - sharewise.com
Analyst Tejas Savant Raises Price Target for Veracyte (VCYT) to $48.00 | VCYT Stock News - GuruFocus
Virtus Advisers LLC Sells 31,958 Shares of Veracyte, Inc. $VCYT - MarketBeat
Morgan Stanley Raises Price Target on Veracyte to $48 From $40, Keeps Underweight Rating - marketscreener.com
Will Veracyte Inc. stock benefit from AI adoptionWeekly Volume Report & Entry and Exit Point Strategies - Newser
Is Veracyte Inc. stock safe for conservative investorsJuly 2025 Setups & Free Accurate Trade Setup Notifications - Newser
Why analysts upgrade Veracyte Inc. stockJuly 2025 Selloffs & Verified Entry Point Detection - Newser
Veracyte (VCYT) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Vinva Investment Management Ltd Purchases New Shares in Veracyte, Inc. $VCYT - MarketBeat
Veracyte Inc Stock (VCYT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Veracyte Inc Stock (VCYT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| EASTHAM KARIN | Director |
Dec 05 '25 |
Sale |
45.45 |
20,000 |
908,923 |
13,554 |
1.15%
0.39%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):